82 Hits in 1.4 sec

Suppressors of Cytokine Signaling and Hepatocellular Carcinoma

Ryota Masuzaki, Tatsuo Kanda, Reina Sasaki, Naoki Matsumoto, Kazushige Nirei, Masahiro Ogawa, Seth J. Karp, Mitsuhiko Moriyama, Hirofumi Kogure
2022 Cancers  
Cytokines are secreted soluble glycoproteins that regulate cellular growth, proliferation, and differentiation. Suppressors of cytokine signaling (SOCS) proteins negatively regulate cytokine signaling and form a classical negative feedback loop in the signaling pathways. There are eight members of the SOCS family. The SOCS proteins are all comprised of a loosely conserved N-terminal domain, a central Src homology 2 (SH2) domain, and a highly conserved SOCS box at the C-terminus. The role of
more » ... proteins has been implicated in the regulation of cytokines and growth factors in liver diseases. The SOCS1 and SOCS3 proteins are involved in immune response and inhibit protective interferon signaling in viral hepatitis. A decreased expression of SOCS3 is associated with advanced stage and poor prognosis of patients with hepatocellular carcinoma (HCC). DNA methylations of SOCS1 and SOCS3 are found in HCC. Precise regulation of liver regeneration is influenced by stimulatory and inhibitory factors after partial hepatectomy (PH), in particular, SOCS2 and SOCS3 are induced at an early time point after PH. Evidence supporting the important role of SOCS signaling during liver regeneration also supports a role of SOCS signaling in HCC. Immuno-oncology drugs are now the first-line therapy for advanced HCC. The SOCS can be potential targets for HCC in terms of cell proliferation, cell differentiation, and immune response. In this literature review, we summarize recent findings of the SOCS family proteins related to HCC and liver diseases.
doi:10.3390/cancers14102549 pmid:35626153 pmcid:PMC9139988 fatcat:gnxkipl4wbacnfbhoeer2abvxe

Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease

Tatsuo Kanda, Reina Sasaki, Ryota Masuzaki, Hiroshi Takahashi, Taku Mizutani, Naoki Matsumoto, Kazushige Nirei, Mitsuhiko Moriyama
2020 International Journal of Molecular Sciences  
Hepatitis A virus (HAV) infection occasionally leads to a critical condition in patients with or without chronic liver diseases. Acute-on-chronic liver disease includes acute-on-chronic liver failure (ACLF) and non-ACLF. In this review, we searched the literature concerning the association between HAV infection and chronic liver diseases in PubMed. Chronic liver diseases, such as metabolic associated fatty liver disease and alcoholic liver disease, coinfection with other viruses, and host
more » ... c factors may be associated with severe hepatitis A. It is important to understand these conditions and mechanisms. There may be no etiological correlation between liver failure and HAV infection, but there is an association between the level of chronic liver damage and the severity of acute-on-chronic liver disease. While the application of an HAV vaccination is important for preventing HAV infection, the development of antivirals against HAV may be important for preventing the development of ACLF with HAV infection as an acute insult. The latter is all the more urgent given that the lives of patients with HAV infection and a chronic liver disease of another etiology may be at immediate risk.
doi:10.3390/ijms21176384 pmid:32887515 fatcat:aaqsuy7isrdxxivuwdp7anaj5q

Regulation of the PRL Promoter by Akt through cAMP Response Element Binding Protein

Jun Hayakawa, Masahide Ohmichi, Keiichi Tasaka, Yuki Kanda, Kazushige Adachi, Yukihiro Nishio, Koji Hisamoto, Seiji Mabuchi, Shuji Hinuma, Yuji Murata
2002 Endocrinology  
Regulation of the PI3K-protein kinase B/Akt (serine/threonine kinase) cascade by PRL-releasing peptide (PrRP) and insulin in GH3 rat pituitary tumor cells was investigated. PrRP and insulin rapidly and transiently stimulated the activation of Akt, and the PI3K inhibitor wortmannin blocked the PrRP-or insulin-induced activation of Akt. Both pertussis toxin (10 ng/ml), which inactivates Gi/Go proteins, and expression of a peptide derived from the carboxyl terminus of the ␤-adrenergic receptor
more » ... se I, which specifically blocks signaling mediated by the ␤␥ subunits of G proteins, completely blocked the PrRP-induced Akt activation, suggesting that Gi/Go proteins are involved in PrRP-induced Akt activation, as they are in the activation of ERK by PrRP. Moreover, to determine whether a PI3K-Akt cascade regulates rat PRL (rPRL) promoter activity, we transfected the intact rPRL promoter ligated to the firefly luciferase reporter gene into
doi:10.1210/endo.143.1.8586 pmid:11751586 fatcat:o2j3dx6p7vb77pvru673wsr2da

A Case of Recent Liver Injury Induced by Benzbromarone

Tomotaka Ishii, Keijiro Hoshino, Masayuki Honda, Yoichiro Yamana, Reina Sasaki-Tanaka, Mariko Kumagawa, Shini Kanezawa, Taku Mizutani, Naoki Matsumoto, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami (+2 others)
2022 Reports  
Kazushige Nirei would like to report lecture fees received from Gilead Sciences, Inc., outside the submitted work.  ...  Conflicts of Interest: Tatsuo Kanda would like to report research grants received from AbbVie Inc. and Towa Pharmaceutical Co., Ltd., and lecture fees received from Gilead Sciences, Inc., AbbVie Inc.,  ... 
doi:10.3390/reports5010008 fatcat:aanjcsh5mrgpdaqsifecznbw4q

Thielocin B3, a novel antiinflammatory human group II phospholipase A2 specific inhibitor from ascomycetes

1994 Journal of antibiotics (Tokyo. 1968)  
doi:10.7164/antibiotics.47.631 fatcat:hr2pqvtpcvbnholj2ioqbxrlra

Variation of Free Amino Acid Concentration in Red Blood Cells of Horse

Seiki WATANABE, Kei HANZAWA, Sachiko KANDA, Michinari YOKOHAMA, Kazushige MOGI
1984 Nihon Chikusan Gakkaiho  
doi:10.2508/chikusan.55.307 fatcat:jv4kylxqsrg2fbloiwr4ozwu2e

Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients

Kazushige Nirei, Tatsuo Kanda, Ryota Masuzaki, Taku Mizutani, Mitsuhiko Moriyama
2021 Medicina  
Conflicts of Interest: Kazushige Nirei would like to report lecture fees received from Gilead Sciences, Inc., outside the submitted work.  ...  Tatsuo Kanda would like to report research grants received from AbbVie Inc. and Towa Pharmaceutical Co., Ltd., and lecture fees received from Gilead Sciences, Inc., AbbVie Inc., and MSD K.K. outside the  ... 
doi:10.3390/medicina57080761 pmid:34440967 pmcid:PMC8399286 fatcat:ctot2lo5hvaldmm5ynawz3obmq

Apoptosis and non-alcoholic fatty liver diseases

Tatsuo Kanda, Shunichi Matsuoka, Motomi Yamazaki, Toshikatsu Shibata, Kazushige Nirei, Hiroshi Takahashi, Tomohiro Kaneko, Mariko Fujisawa, Teruhisa Higuchi, Hitomi Nakamura, Naoki Matsumoto, Hiroaki Yamagami (+4 others)
2018 World Journal of Gastroenterology  
Cell death and NASH Kanda T et al . Cell death and NASH © 2018 Baishideng Publishing Group Inc. All rights reserved.  ...  Lipopolysaccharide Oxidative stress Endoplasmic reticulum stress Autophagy July 7, 2018|Volume 24|Issue 25| WJG| July 7, 2018|Volume 24|Issue 25| WJG| Kanda  ... 
doi:10.3748/wjg.v24.i25.2661 pmid:29991872 pmcid:PMC6034146 fatcat:i3llf4bqjvffna7hih3jqcbgpq


Kouji TOMINAGA, Kazushige ARAI, Hiroshi ISHII, Mitsuo KUSANO, Kazuhiko SOEJIMA, Mikio KANDA
1995 Journal of The Showa Medical Association  
There have been many histopathological studies on the gallbladder in cholecysti tis, but reports of inflammatory changes in the cystic duct are few . Through operative fin dings, the inflammatory changes in the cystic duct seemed to be more mild than those in the gallbladder in cholecystitis. In this study, we comparatively evaluated the inflammatory chan ges between the gallbladder and cystic duct. A total of 103 patients were entered in this study ; 95 patients had received cholecystectomy ,
more » ... nd 8 specimen were obtained from autop sy. In 24 patients (47.1%) with cholecystolithiasis and in 3 patients (30 .0%) with cholecystocholedocholithiasis, the degree of infiltration of the inflammatory cells in cystic ducts was more mild than those in the neck of the gallbladder . The degree of fibrosis of the wall of the cystic duct was similar to that of the neck of the gallbladder , or it was more mild. In the correlation of the infiltration of the inflammatory cells and the fibrosis of the wall , the patients with fibrotic changes in the gallbladder had more advanced infiltration of inflamma tory cells. As for the accumulation of elastic fibers , in 11 patients (19.7%) with cholecystolithiasis and 1 patient (10.0%) with cholecystocholedocholithiasis , it was more prominent in the cystic duct than in the neck of gallbladder . Among patients with cholecystolithiasis and cholecystocholedocholithiasis, none with accompanying mild infiltration of inflammatory cells and fibrosis of the wall, had severe accumulation of elastic fiber . In this study, we found that inflammatory changes of the cystic duct was less noted than that of the neck of the gall bladder. Cystic duct has a helical-line structure which produces two converse flows of bile . This structural characteristic may play a role in defending the choledochus from the spread of cholecystitis.
doi:10.14930/jsma1939.55.253 fatcat:rt3cm24b2rhbviyh7g6ldqbuue

Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection

Kazushige Nirei, Tatsuo Kanda, Hitomi Nakamura, Shunichi Matsuoka, Tadatoshi Takayama, Masahiko Sugitani, Mitsuhiko Moriyama
2018 International Journal of Medical Sciences  
I In nt te er rn na at ti io on na al l J Jo ou ur rn na al l o of f M Me ed di ic ca al l S Sc ci ie en nc ce es s 2018; 15(5): 466-474. Abstract Objective: Hepatitis C virus (HCV) infection has long been treated with interferon therapy (IFN). Currently, more than 90% of IFN-treated patients show a sustained virological response (SVR) when also treated with ribavirin and/or a protease inhibitor. Histological inflammation and fibrosis improve in IFN-treated patients, which indicates HCV
more » ... e. IFN also reduces the incidence of hepatocellular carcinoma (HCC). However, a small proportion of patients with SVR develop HCC. To investigate the causes of hepatic carcinogenesis after SVR, we compared the liver histological findings before IFN to those after the development of HCC. Patients and methods: In total, 602 patients infected with type C chronic hepatitis or with liver cirrhosis who received IFN therapy during the period from 1992 through 2015 were included in this study. We assessed 14 of the 287 patients who achieved an SVR. Results: HCC was diagnosed by computed tomography, angiography or liver biopsy. The longest time from the SVR until HCC detection was 16.5 years, and the mean was 7.2±4.6 years. Nine of the 14 patients underwent surgery and one radiofrequency ablation. The histological findings of 10 patients were available for comparison. The comparison of the histological findings before treatment with those after the HCC diagnosis revealed an amelioration of liver fibrosis and other inflammatory changes. All ten patients showed improvements in fibrosis and steatosis. However, we observed that mild inflammatory change persisted from 1.8 years to 16.5 years after the confirmation of SVR in all cases. Conclusion: We suspect that persistent histological inflammation is one of the factors contributing to hepatocarcinogenesis (i.e., HCC development) even after successful treatment.
doi:10.7150/ijms.23147 pmid:29559835 pmcid:PMC5859769 fatcat:lagpz2nrtvfkxery474mqhwdfa

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b

Tatsuo Kanda, Kazushige Nirei, Naoki Matsumoto, Teruhisa Higuchi, Hitomi Nakamura, Hiroaki Yamagami, Shunichi Matsuoka, Mitsuhiko Moriyama
2017 World Journal of Gastroenterology  
There is no doubt that new, more effective combinations of DAAs have appeared and will continue Kanda T et al.  ... 
doi:10.3748/wjg.v23.i46.8120 pmid:29290649 pmcid:PMC5739919 fatcat:glbwh4qum5bmpe5tjfjv35ujm4

Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells

Koji Hisamoto, Masahide Ohmichi, Hirohisa Kurachi, Jun Hayakawa, Yuki Kanda, Yukihiro Nishio, Kazushige Adachi, Keiichi Tasaka, Eiji Miyoshi, Noriko Fujiwara, Naoyuki Taniguchi, Yuji Murata
2000 Journal of Biological Chemistry  
., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., and Murata, Y. (2000) Cancer Res. 60, 5988 -5994.  ... 
doi:10.1074/jbc.m005036200 pmid:11044445 fatcat:lee4csyxxbeszljhtxjc6ntbuq

Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease

Masahiro Ogawa, Tatsuo Kanda, Teruhisa Higuchi, Hiroshi Takahashi, Tomohiro Kaneko, Naoki Matsumoto, Kazushige Nirei, Hiroaki Yamagami, Shunichi Matsuoka, Kazumichi Kuroda, Mitsuhiko Moriyama
2019 International Journal of Medical Sciences  
Competing Interests Tatsuo Kanda and Mitsuhiko Moriyama received research grants from AbbVie, Eisai, Daiichi-Sankyo, Shionogi, Mitsubishi-Tanabe Pharma, Astellas, Ono Pharma and Takeda Pharma.  ... 
doi:10.7150/ijms.34245 pmid:31341404 pmcid:PMC6643132 fatcat:rd7vvdtqbvfwpodvbrwble5fw4

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan

Yoichiro Yamana, Tatsuo Kanda, Naoki Matsumoto, Masayuki Honda, Mariko Kumagawa, Reina Sasaki, Shini Kanezawa, Taku Mizutani, Hiroaki Yamagami, Ryota Masuzaki, Tomotaka Ishii, Kazushige Nirei (+1 others)
2021 Journal of Clinical Medicine  
Kazushige Nirei would like to report lecture fees received from Gilead Sciences, Inc., outside the submitted work.  ...  Conflicts of Interest: Tatsuo Kanda would like to report research grants received from AbbVie Inc. and Towa Pharmaceutical Co., Ltd., and lecture fees received from Gilead Sciences, Inc., AbbVie Inc.,  ... 
doi:10.3390/jcm10235529 pmid:34884231 fatcat:si6phkmacrc7fap6eeucz2fika

COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case Report

2022 In Vivo  
Eradication of hepatitis C virus (HCV) from chronic HCV-infected patients could improve liver function and prevent hepatocarcinogenesis in the long term. Eradication of HCV by direct-acting antivirals (DAAs) also leads to dynamic immunological changes. We report a case of recurrent coronavirus disease 2019 (COVID-19) that developed immediately after combination treatment with DAAs for HCV infection and decompensated cirrhosis. A 55-year-old male was started on a 12-week treatment with
more » ... n of HCV NS5A inhibitor velpatasvir and HCV NS5B polymerase inhibitor sofosbuvir. HCV RNA became undetectable after six weeks of treatment and was undetectable at the end of the treatment (EOT). Twelve days after the EOT, we diagnosed the patient with COVID-19 pneumonia, admitted him to our hospital and he was discharged two weeks later. One week after his discharge, he visited our hospital again, was diagnosed with recurrent COVID-19 pneumonia readmitted for a second time. Four days after second admission, cardiac arrest occurred, however, he recovered from severe COVID-19 and achieved sustained virological response and his liver function improved. In the COVID-19 era, while attention should be paid to the occurrence or exacerbation of infection, including COVID-19, interferon-free DAA combination therapy should be performed for HCV-infected individuals.
doi:10.21873/invivo.12923 pmid:35738621 pmcid:PMC9301408 fatcat:5n675p3vp5hpxafkgxykenpduq
« Previous Showing results 1 — 15 out of 82 results